{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Total # of Participants with Dose Reductions for Any Reason"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Dose Reduction for Corneal Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Dose Reduction for Hematologic Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dose Reduction for Other Reason"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Number of participants for whom BLENREP dosing was dose reduced during treatment as categorized by reason.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Treatment Characteristics: Dosing Patterns - Dose Reductions During Treatment With BLENREP Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}